When patients march in

Nature Biotechnology

Volumn 28, Issue 11, 2010, Pages 1145-1148

  Hughes, Virginia ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE BETA;

ATAXIA TELANGIECTASIA; BIOTECHNOLOGY; CLINICAL RESEARCH; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DUCHENNE MUSCULAR DYSTROPHY; FABRY DISEASE; GAUCHER DISEASE; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; PATIENT ADVOCACY; PHARMACOGENOMICS; PRIORITY JOURNAL; PSEUDOXANTHOMA ELASTICUM; SHORT SURVEY;

CONFLICT (PSYCHOLOGY); COOPERATIVE BEHAVIOR; DRUG CONTAMINATION; DRUG INDUSTRY; ENZYME REPLACEMENT THERAPY; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; INDIVIDUALIZED MEDICINE; INVESTMENTS; PATENTS AS TOPIC; PATIENT ADVOCACY;

EID: 78149311462     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt1110-1145     Document Type: Short Survey

References (4)

1. Struk, B. et al., Hum. Mol. Genet. 6, 1823-1828 (1997)
2. LeSaux, O. et al. Nat. Genet. 25, 223-227 (2000).
3. Ayme, S., Kole, a. & Groft, S. Lancet 371, 2048-2051 (2008).
4. Terry, S.F., Terry, P.F., rauen, K.a., uitto, J. & Bercovitch, L.G. Nat. Rev. Genet. 8, 157-164 (2007).